AI assistant
Vistin Pharma — Earnings Release 2018
Feb 19, 2019
3782_rns_2019-02-19_4b93b819-3ef1-48f8-9156-fc3ea381c0db.html
Earnings Release
Open in viewerOpens in your device viewer
Vistin Pharma ASA : Fourth quarter 2018 financial results
Vistin Pharma ASA : Fourth quarter 2018 financial results
Oslo, Norway, 19 February 2019
Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial
results for the fourth quarter of 2018 in line with the business updates from
the company on 4 and 8 January 2019.
The revenues for the fourth quarter 2018 ended at NOK 40.1 million (Q4 2017: NOK
41.3 million).
The loss from continuing operations ended at NOK -56.4 million (-6.8) in the
fourth quarter 2018, mainly following the unrealised financial loss on oil
derivatives of NOK 65.2 million for the period. Vistin Pharma announced in
January 2019 to close the Energy Trading business and provided an update on the
unrealised financial loss on 4 and 8 January 2019.
Vistin Pharma will continue to manage the outstanding financial derivative
contracts, and some or all of these may be closed when the company believes this
to be in the best interest of its shareholders.
Vistin Pharma had cash of NOK 320.7 million as of 31 December 2018, and no
interest-bearing debt.
The fourth quarter conference call will be available via web and audio through
the following access points:
Telephone conference:
Confirmation Code:........ 8759564
International Dial-In: ..... +44 (0) 2071 928000
Norway, Oslo................. 21563012
United States, New York. 16467740219
Webcast:
https://edge.media-server.com/m6/p/ustfvg7g
Please find the report for the fourth quarter 2018 enclosed. The report will
also be made available on www.vistin.com.
*****
For further information, please contact:
Kjell-Erik Nordby
CEO
+47 91 36 42 80
Gunnar Manum
CFO
+47 95 17 91 90
About Vistin Pharma | www.vistin.com
Vistin Pharma is a Norwegian pharmaceutical company producing Metformin
Hydrochloride (API). The Metformin is also available as Direct Compressible
lubricated granules. As a solely dedicated European Metformin producer, Vistin
Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin
Pharma is headquartered in Oslo, Norway, and has highly qualified employees and
a dedicated manufacturing facility in Kragerø.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.